Crispr Therapeutics AG (CRSPN) Stock Statistics & Valuation Metrics

Crispr Therapeutics AG has a market cap or net worth of MXN 93.43B. The enterprise value is MXN 3.68B.

Market Cap

MXN 93.43B

Enterprise Value

MXN 3.68B

Crispr Therapeutics AG has 96,692,650 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

96,692,650

Owned by Insiders

2.61%

Owned by Institutions

36.64%

Crispr Therapeutics AG’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -26.62%.

Return on Equity (ROE)

-0.30

Return on Assets (ROA)

-0.26

Return on Invested Capital (ROIC)

-26.62%

Return on Capital Employed (ROCE)

-0.27

Revenue Per Employee

8,931.298

Profits Per Employee

-1.48M

Employee Count

393

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Crispr Therapeutics AG is -10.80. Crispr Therapeutics AG’s PEG ratio is -2.40.

PE Ratio

-10.80

PS Ratio

371.26

PB Ratio

2.84

Price to FCF

-13.30

Price to Operating Cash Flow

-13.43

PEG Ratio

-2.40

In the last 12 months, Crispr Therapeutics AG had revenue of 3.51M and earned -581.60M in profits. Earnings per share was -6.47.

Revenue

3.51M

Gross Profit

-229.45M

Operating Income

-568.32M

Pretax Income

-577.97M

Net Income

-581.60M

EBITDA

-558.49M

Earnings Per Share (EPS)

-6.47

In the last 12 months, operating cash flow was -369.58M and capital expenditures -4.22M, giving a free cash flow of -373.80M billion.

Operating Cash Flow

-369.58M

Free Cash Flow

-373.80M

Free Cash Flow per Share

-3.87

Crispr Therapeutics AG pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-7.52%

Earnings Yield

-9.09%

Beta

-0.11

52-Week Price Change

-21.83%

50-Day Moving Average

957.85

200-Day Moving Average

918.05

Relative Strength Index (RSI)

27.32

Average Volume (3m)

173

Crispr Therapeutics AG upcoming earnings date is Nov 04, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 03, 2026

Next Earnings Date

Nov 04, 2026

Ex-Dividend Date

―

Crispr Therapeutics AG as a current ratio of 13.32, with Debt / Equity ratio of 20.55%

Current Ratio

13.32

Quick Ratio

13.32

Debt to Market Cap

0.04

Net Debt to EBITDA

-0.07

Interest Coverage Ratio

0.00

In the past 12 months, Crispr Therapeutics AG has paid 3.63M in taxes.

Income Tax

3.63M

Effective Tax Rate

-0.01

Crispr Therapeutics AG EV to EBITDA ratio is -12.04, with an EV/FCF ratio of -14.62.

EV to Sales

408.03

EV to EBITDA

-12.04

EV to Free Cash Flow

-14.62

EV to Operating Cash Flow

-14.79

Crispr Therapeutics AG has MXN 2.36B in cash and marketable securities with MXN 783.75M in debt, giving a net cash position of MXN 1.58B billion.

Cash & Marketable Securities

MXN 2.36B

Total Debt

MXN 783.75M

Net Cash

MXN 1.58B

Net Cash Per Share

MXN 16.35

Tangible Book Value Per Share

MXN 18.10

Gross margin is -1534.39%, with operating margin of -3971.53%, and net profit margin of -3368.72%.

Gross Margin

-1534.39%

Operating Margin

-3971.53%

Pretax Margin

-3346.08%

Net Profit Margin

-3368.72%

EBITDA Margin

-3390.20%

EBIT Margin

-3529.79%

The average price target for Crispr Therapeutics AG is MXN 1,336.94, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

MXN 1,336.94

Price Target Upside

46.11% Upside

Analyst Consensus

Moderate Buy

Analyst Count

13

Revenue Growth Forecast

-69.22%

EPS Growth Forecast

19.84%

Smart Score

2

AI Score

―